Results 121 to 130 of about 50,213 (312)

Capsaicin-Induced Ca2+ Influx and Constriction of the Middle Meningeal Artery [PDF]

, 2014
Research in the past on transient receptor potential cation channel subfamily V member 1 (TRPV1) has been limited to mainly nervous tissue TRPV1 because of the channel’s role in pain perception.
Koide, Masayo, Kotlikoff, Michael I., Manuelyan, Inessa, Shui, Bo, Syed, Arsalan U., Wellman, George C.   +5 more
core   +1 more source

Action of Calcitonin Gene-related Peptide (CGRP) and Substance P on Neurons in the Insular Cortex and the Modulation of Taste Responses in the Rat [PDF]

, 2000
Hiroshi Ogawa
openalex   +1 more source

Efficacy and Safety of Rimegepant 75 Mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial [Corrigendum]

Journal of Pain Research
Lipton RB, Thiry A, Morris BA, Croop R. J Pain Res. 2024 Jul 22:17:2431–2441. The authors have advised that Figure 2 on page 2437 is incorrect. The text “150/241 (27.7%)” in the Placebo n/N (Risk) column for the row Freedom from MBS ...
Lipton RB, Thiry A, Morris BA, Croop R
doaj  

Reduction of opioid and barbiturate use following initiation of rimegepant for migraine in the United States

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective The primary objective of this study was to evaluate opioid and barbiturate utilization before and after the first prescription of the calcitonin gene–related peptide receptor antagonist rimegepant in individuals with migraine. Background Although not recommended in migraine treatment guidelines, opioids and barbiturates are often ...
Noah Rosen, Aaron Jenkins, Karin Hygge Blakeman, Feng Dai, Lucy Abraham, Chelsea Leroue, Josh Brown   +6 more
wiley   +1 more source

A single-nucleus RNA-sequencing pipeline to decipher the molecular anatomy and pathophysiology of human kidneys [PDF]

, 2019
Defining cellular and molecular identities within the kidney is necessary to understand its organization and function in health and disease. Here we demonstrate a reproducible method with minimal artifacts for single-nucleus Droplet-based RNA sequencing (
Chen, Song, Gao, Derek, Gaut, Joseph, Hoshi, Masato, Jain, Sanjay, Kim, Eric H., Knoten, Amanda, Lake, Blue B., Plongthongkum, Nongluk, Salamon, Diane, Venkatesh, Ramakrishna, Vijayan, Anitha, Zhang, Kun   +12 more
core   +2 more sources

Efficacy and Safety of Rimegepant 75 mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial

Journal of Pain Research
Richard B Lipton,1 Alexandra Thiry,2 Beth A Morris,3 Robert Croop3 1Department of Neurology and the Montefiore Headache Center, Albert Einstein College of Medicine, Bronx, NY, USA; 2Biostatistics, Pfizer, Inc., New York, NY, USA; 3Clinical Operations (BM)
Lipton RB, Thiry A, Morris BA, Croop R
doaj  

Changes in brainstem habituation during onabotulinumtoxinA treatment in chronic migraine: A prospective case–control study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background Chronic migraine is a debilitating neurological disorder characterized by central sensitization and impaired brainstem habituation. OnabotulinumtoxinA is an established prophylactic treatment for chronic migraine, yet its effects on central trigeminal sensory processing remain incompletely understood.
Gerlinde Freimark, Sebastian Strauss, Lucas H. Overeem, Mira P. Fitzek, Kristin S. Lange, Carolin L. Höhne, Uwe Reuter, Robert Fleischmann, Bianca Raffaelli   +8 more
wiley   +1 more source

A novel bioactive peptide-peptoid hybrid of alpha-calcitonin gene-related peptide protects against pressure-overload induced heart failure

Frontiers in Pharmacology
BackgroundAlpha-calcitonin gene-related peptide (α-CGRP) is a cardioprotective neuropeptide. However, due to low bioavailability, its use as a therapeutic agent is limited.
Ambrish Kumar, Sarah Deloach, Lernix Williams, Donald J. DiPette, Jay D. Potts   +4 more
doaj   +1 more source

Effectiveness and tolerability of galcanezumab for migraine prevention in patients ≥65 years: A real‐life multicenter study

Headache: The Journal of Head and Face Pain, EarlyView.
Plain Language Summary This study shows that galcanezumab is equally effective and well‐tolerated in patients aged 65 and older as in younger patients, with a higher proportion of excellent responders in older patients. Despite having more baseline headache days, older patients responded well to the treatment, with age being linked to better outcomes ...
Julia Peris‐Subiza, Víctor Obach, Daniel Guisado‐Alonso, Fernando Velasco Juanes, Rocío Álvarez Escudero, María Martín Bujanda, Sonsoles Aranceta, Aintzine Ruisánchez, Natalia Roncero, Ane Mínguez‐Olaondo, Amaya Echeverria, Alba López‐Bravo, Ángel Luis Guerrero‐Peral, David García‐Azorín, Elisa Cuadrado‐Godia, Galca‐Only Study Group, Neus Fabregat, Marta Ruibal, Izaro Kortazar Zubizarreta, Nuria Riesco, Lucia González‐Fernández, Paula Manera, Agustín Oterino Duran, Yésica González‐Osorio, Santiago Fernández‐Fernández, Juan Carlos García‐Moncó, Isabel Fernández‐Pérez, Joan Jiménez‐Balado   +27 more
wiley   +1 more source

Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: A real-world evidence study [PDF]

, 2023
Alicia Alpuente, Anna de la Torre-Suñe, Edoardo Caronna, Eulàlia Giné-Ciprés, Marta Torres‐Ferrús, Patricia Pozo‐Rosich   +5 more
openalex   +1 more source